Scientific deep-dive

Does Tirzepatide Lower Atrial Fibrillation Risk? What a 2026 Meta-Analysis Found

A 2026 meta-analysis of 10 placebo-controlled trials found no clear link between tirzepatide and atrial fibrillation in either direction, plus a cautious signal for arrhythmia overall. Here is how that fits with class-level and observational data.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
7 min read·13 citations

No trial evidence shows that tirzepatide lowers atrial fibrillation risk. A 2026 meta-analysis of 10 placebo-controlled trials in adults with overweight or obesity found a pooled odds ratio of 2.20 (95% credible interval 0.81 to 6.75), an estimate too imprecise to show either harm or benefit, and its authors concluded tirzepatide “was not associated with atrial fibrillation.”[1] The same analysis did find higher odds of arrhythmia overall, which the authors urged readers to interpret cautiously.[1]

About this article

This page covers tirzepatide specifically. Our GLP-1 and atrial fibrillation review covers the wider drug class, the weight-loss cohorts, and anticoagulation. The published abstract of the new meta-analysis doesn’t list which trials it included or how each one detected arrhythmia.

What the 2026 meta-analysis found

Mansouri and colleagues, writing in the Journal of the American Heart Association, searched PubMed, Embase, and the Cochrane Library for randomized trials comparing tirzepatide with placebo in people with overweight or obesity.[1] They identified 10 trials with 6,515 participants, 4,491 of whom (68.9%) were assigned to tirzepatide.[1] Because arrhythmia events were rare, they used a Bayesian hierarchical model designed for rare outcomes, which reports credible intervals where a conventional analysis would report confidence intervals.[1]

  • Atrial fibrillation: odds ratio 2.20 (95% credible interval 0.81 to 6.75).[1]
  • Atrial arrhythmia: odds ratio 2.16 (95% credible interval 0.90 to 5.87).[1]
  • Any arrhythmia: odds ratio 1.84 (95% credible interval 1.04 to 3.90).[1]

The atrial fibrillation interval is the part to read closely. It runs from a modest reduction in odds to nearly a sevenfold increase, and it includes 1.0, the value for no difference.[1] That result means the data can’t settle the question. It doesn’t establish that tirzepatide raises risk, and it doesn’t establish that the drug is neutral. The any-arrhythmia interval sits just above 1.0 at its lower end, and the authors said “event rates were low.”[1] The abstract gives no breakdown of which arrhythmias drove that signal.

Why class-level results point the other way

A reader who has seen headlines about GLP-1 drugs preventing atrial fibrillation may find this confusing. Those headlines come from analyses of a broader group of drugs and much larger totals. Karakasis and colleagues pooled 24 trials with 40,694 participants and reported a risk ratio of 0.82 (95% CI 0.70 to 0.96) for GLP-1 receptor agonists and co-agonists against placebo in overweight or obesity.[2] They found no significant difference between subgroups by agent type or individual compound, though a null subgroup test has limited power.[2]

A European Heart Journal meta-analysis of 249 trials across cardio-renal-metabolic drugs reported, among placebo-controlled obesity trials, a risk ratio of 0.79 (95% CI 0.63 to 0.99) for GLP-1 receptor agonists.[3] Its authors added a caveat that applies to this whole literature: across all drug classes, 207 of the 249 trials identified atrial fibrillation through adverse event reports, only 15 had it as a pre-specified endpoint, and “none were adequately powered for incident AF.”[3] The abstract doesn’t say whether tirzepatide trials contributed to that obesity estimate.

Tirzepatide and atrial fibrillation: what each analysis compared
AnalysisPopulation and comparisonSizeAtrial fibrillation result
Mansouri 2026Overweight or obesity; tirzepatide vs placebo10 RCTs, 6,515 peopleOR 2.20 (95% CrI 0.81 to 6.75)
Wu R 2025Type 2 diabetes; tirzepatide trials, with subgroups by comparator type12 RCTs, 10,615 peopleRR 1.39 (95% CI 0.53 to 3.67)
Karakasis 2026Overweight or obesity; GLP-1 drugs and co-agonists vs placebo24 RCTs, 40,694 peopleRR 0.82 (95% CI 0.70 to 0.96)
Barbosa 2026Diabetes or obesity; subcutaneous semaglutide vs tirzepatide, network estimate94 RCTs, 155,989 peopleRR 0.57 (95% CI 0.37 to 0.88)

The diabetes data lean the same way as the obesity data and are similarly imprecise. A meta-analysis of 12 trials with 10,615 patients reported a risk ratio of 1.39 (95% CI 0.53 to 3.67) for atrial fibrillation.[5] Its search ended in February 2025, before the largest tirzepatide outcomes trial was published.[5][6]

Semaglutide versus tirzepatide: conflicting signals

A network meta-analysis published online ahead of print in Heart Rhythm ranked subcutaneous semaglutide highest for atrial fibrillation among 12 drugs, with a risk ratio of 0.82 (95% CI 0.68 to 0.99) against placebo and 0.57 (95% CI 0.37 to 0.88) against tirzepatide.[4] Tirzepatide’s ranking score was 0.1830 against semaglutide’s 0.7885, on a scale where 1 is best.[4] A network estimate combines evidence across different trials, so this isn’t a head-to-head trial powered for atrial fibrillation, and the authors said further studies focused on arrhythmia are needed.[4]

Observational data run in the opposite direction. A target trial emulation in the TriNetX health-record network, covering 217,920 adults starting either drug, reported that tirzepatide was associated with lower risk across all its outcomes, atrial fibrillation among them, at 1 and 3 years.[8] At 3 years the risk ratios for atrial fibrillation with tirzepatide versus semaglutide were 0.773 (95% CI 0.737 to 0.811) with diabetes and 0.743 (95% CI 0.690 to 0.801) without it.[8] Record-based studies remain open to confounding by who gets prescribed which drug. Neither source settles which drug is better for heart rhythm. They disagree, and each has limits that could explain the disagreement.

The large outcomes trial doesn't answer this

SURPASS-CVOT randomized 13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide (up to 15 mg) or dulaglutide (1.5 mg).[6] The primary endpoint of cardiovascular death, heart attack, or stroke occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group, a hazard ratio of 0.92 (95.3% CI 0.83 to 1.01), which met noninferiority but not superiority.[6] The trial was funded by Eli Lilly.[6] Atrial fibrillation isn’t an outcome reported in its abstract, and the active comparator means it could not qualify for a placebo-only analysis like the 2026 meta-analysis.[1][6]

If you already have atrial fibrillation

The meta-analysis addresses new arrhythmia events in trial participants, which is a different question from how tirzepatide affects people who already have the condition. Here the evidence is observational. In a TriNetX cohort of 11,194 matched patients with both atrial fibrillation and type 2 diabetes, tirzepatide use was associated with a lower risk of a composite of cardioversion, intravenous antiarrhythmic use, and ablation (HR 0.65, 95% CI 0.55 to 0.76).[7] Those are treatment decisions recorded in charts, used as a stand-in for arrhythmia burden, and the authors called for prospective evaluation.[7]

There is a plausible mechanism, though it remains unproven for rhythm. In a substudy of the SUMMIT heart failure trial, 106 patients with analyzable scans had paracardiac fat fall by 45 mL (95% CI −69 to −22 mL) and left ventricular mass fall by 11 g (95% CI −19 to −4 g) relative to placebo at 52 weeks.[9] Arrhythmia was not the substudy’s endpoint.[9]

Randomized tests are registered. TIRO-AF, a single-center, double-blind phase 2 trial with an estimated 100 participants, compares tirzepatide with placebo using atrial fibrillation burden as its primary outcome.[11] A separate multicenter, open-label trial with an estimated 710 participants looks at recurrence after catheter ablation.[12] Both enroll people who already have the arrhythmia, so even clear results would not tell us whether tirzepatide prevents a first episode.

What the Zepbound label says

In the pooled Study 1 and 2 data in the Zepbound prescribing information, treatment “resulted in a mean increase in heart rate of 1 to 3 beats per minute compared to no increase in placebo-treated patients.”[10] The August 2026 revision doesn’t name atrial fibrillation.[10] A faster resting pulse is a separate issue from an irregular rhythm, and no source reviewed here links the two for this drug; our tirzepatide heart rate guide covers that effect in detail. Individual events do get reported: one case report describes a 62-year-old woman who developed new-onset atrial fibrillation shortly after starting tirzepatide, with no recurrence after stopping.[13] A single case can’t establish that the drug was the cause.

What to raise with a prescriber

  • Palpitations, a racing or irregular pulse, fainting, or breathlessness after starting tirzepatide deserve prompt medical attention, whatever the population data show.
  • If you have atrial fibrillation, ask whether your rhythm plan or anticoagulant needs review as your weight changes, and don’t change either on your own.
  • If you are choosing between tirzepatide and semaglutide, ask how much weight to give to arrhythmia data. The comparisons above conflict, and none came from a trial built to test this.
  • Don’t count on tirzepatide as atrial fibrillation prevention. No randomized trial reviewed here shows that effect.

Our reviews

Providers that offer tirzepatide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

Randomized trials have not shown that. A 2026 meta-analysis of 10 placebo-controlled trials in adults with overweight or obesity found an odds ratio of 2.20 with a 95% credible interval of 0.81 to 6.75. That range includes no difference, so the data do not establish either a reduction or an increase.
That has not been established. The 2026 meta-analysis concluded tirzepatide was not associated with atrial fibrillation, though its estimate was imprecise. It did find higher odds of any arrhythmia, with an odds ratio of 1.84 and an interval of 1.04 to 3.90, and the authors urged caution because event rates were low. Report palpitations or an irregular pulse to a clinician.
The evidence conflicts. A network meta-analysis favored subcutaneous semaglutide over tirzepatide for atrial fibrillation, with a risk ratio of 0.57, while a large health-record study associated tirzepatide with lower risk than semaglutide. Neither is a head-to-head trial designed for this outcome, so it is a question to discuss with a prescriber using your full history.
The August 2026 Zepbound label does not name atrial fibrillation, but that is not proof of safety in this group. A health-record study in people with atrial fibrillation and type 2 diabetes linked tirzepatide to fewer rhythm procedures, which is observational. Randomized trials in this group are registered. Your cardiologist and prescriber should weigh your case, and anticoagulants should not be changed without them.

References

  1. 1.Mansouri ES, Queiroga F, Barbosa LM, Azevedo AK, Donaldy W, Mirbolouk MJ, Blair CV, Rivera A, Ferreira Felix I, Abreu M, Deshmukh AJ, DeSimone CV. Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2026. PMID: 42714458.
  2. 2.Karakasis P, Vlachos K, Antoniadis AP, Siontis KC, Patoulias D, Fragakis N, Mantzoros CS. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2026. PMID: 41349790.
  3. 3.Raveendra K, Nadarajah R, Larvin H, Farooq M, Haris M, Cutting U, Kang J, Wilkinson C, Dalakoti M, Kotecha D, Lip GYH, Boriani G, Camm AJ, Van Gelder IC, Wu J, Gale CP. Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis. Eur Heart J. 2026. PMID: 41603358.
  4. 4.Barbosa LM, Rodrigues Oliveira VM, Ruelas MG, Nascimento BR, Moreira HG, Nunes MDCP, Darrieux F, Lopes RD, Boriani G, Lip GYH. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis. Heart Rhythm. 2026. PMID: 42933519.
  5. 5.Wu R, Xing B, Zhou Z, Yu L, Wang H. Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. Neurol Sci. 2025. PMID: 41402646.
  6. 6.Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, et al; SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025. PMID: 41406444.
  7. 7.Wu JY, Tseng KJ, Kao CL, Hung KC, Yu T, Lin YM. Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study. Diabetes Res Clin Pract. 2025. PMID: 40412626.
  8. 8.Azzam AY, Essibayi MA, Rai P, Salim HA, Alhasan MS, Anindo M, Hashem A, Dmytriw AA, Altschul DJ, Yedavalli VS, Feltrin F, Singh S, Milburn J, Lakhani DA. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation. JACC Adv. 2026. PMID: 42489387.
  9. 9.Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V, Ou Y, Zarante AM, Hurt KC, Murakami M, Packer M; SUMMIT Trial Study Group. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. J Am Coll Cardiol. 2025. PMID: 39566869.
  10. 10.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  11. 11.ClinicalTrials.gov. TIRO-AF: TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation (NCT06802081). ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT06802081
  12. 12.ClinicalTrials.gov. Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients (NCT07715929). ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT07715929
  13. 13.Purvez A, Mirza M, Bashir M. New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report. Cureus. 2025. PMID: 41425685.

Mounjaro and Blood Pressure: Does Tirzepatide Lower It? (2026)

Mounjaro (tirzepatide) modestly lowers blood pressure rather than raising it, a drop of about 7-11 mmHg driven largely by weight loss in a SURMOUNT-1 24-hour monitoring substudy. It can overshoot with dehydration or BP medicines, so report dizziness on standing.

8 min read

Mounjaro and Heart Rate: Why Tirzepatide Raises Your Pulse (and What It Means) (2026)

Mounjaro (tirzepatide) raises resting heart rate modestly, about 2-5 bpm on average, a labeled effect. SURPASS-CVOT found it noninferior to dulaglutide for heart events. How to tell a pulse rise from palpitations, and the red flags to report.

8 min read

Does Tirzepatide Help You Live Longer? Mortality and Longevity Evidence

Does Zepbound or Mounjaro help you live longer? A 2026 meta-analysis found lower all-cause mortality and real-world data agree, but tirzepatide's dedicated outcomes trial in obesity, SURMOUNT-MMO, is still running. What the evidence shows on survival, healthspan and aging.

8 min read

Who Qualifies for GLP-1 Weight-Loss Medication? The FDA Label Criteria

Who qualifies for Wegovy, Zepbound, Saxenda, or Foundayo under the FDA labels: adult BMI rules, teen percentile rules, the heart, MASH, and sleep apnea approvals, how to calculate BMI, and why insurance criteria differ.

10 min read

SURPASS-CVOT: Tirzepatide Cardiovascular Outcomes (2026)

SURPASS-CVOT (NEJM 2025) tested tirzepatide vs dulaglutide in 13,299 adults with type 2 diabetes and heart disease: MACE 12.2% vs 13.1%, HR 0.92 — non-inferior.

13 min read

GLP-1 and HFrEF Heart Failure: The Evidence (2026)

GLP-1 drugs help in HFpEF, but the randomized HFrEF trials (FIGHT, LIVE) of liraglutide showed no benefit, a faster heart rate, and possible harm signals.

12 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $209/mo (2-month plan rate)

Get started →
7.2

HumeCare+

GLP-1 weight loss with real-time body-composition tracking to protect muscle

Read full review →

From $299/mo

Get started →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $69/mo (+ required membership)

Get started →